INOZYME PHARMA, INC. Operating Expenses
INOZYME PHARMA, INC. reported Operating Expenses of $27.69 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2025-05-14
- INOZYME PHARMA, INC. operating expenses for the quarter ending 2025-03-31 was $27.69M, a 13.73% increase year-over-year.
- INOZYME PHARMA, INC. operating expenses for the quarter ending 2024-12-31 was $27.17M, a 19.13% increase year-over-year.
- INOZYME PHARMA, INC. operating expenses for the quarter ending 2024-09-30 was $24.85M, a 37.50% increase year-over-year.
- INOZYME PHARMA, INC. operating expenses for the quarter ending 2024-06-30 was $27.66M, a 68.75% increase year-over-year.
- INOZYME PHARMA, INC. operating expenses for fiscal 2024 was $104.03M, a 37.52% increase from fiscal 2023.
- INOZYME PHARMA, INC. operating expenses for fiscal 2023 was $75.64M, a 10.15% increase from fiscal 2022.
- INOZYME PHARMA, INC. operating expenses for fiscal 2022 was $68.67M, a 21.24% increase from fiscal 2021.
- INOZYME PHARMA, INC. operating expenses for fiscal 2021 was $56.65M, a 0.69% decline from fiscal 2020.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2025-03-31 | $27.69M 10-Q · filed 2025-05-14 | $54.86M derived: sum of 2 quarters · filed 2025-05-14 | $79.71M derived: sum of 3 quarters · filed 2025-05-14 | $107.38M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | $27.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $52.02M derived: sum of 2 quarters · filed 2025-03-10 | $79.69M derived: sum of 3 quarters · filed 2025-03-10 | $104.03M 10-K · filed 2025-03-10 |
| 2024-09-30 | $24.85M 10-Q · filed 2024-11-05 | $52.52M derived: sum of 2 quarters · filed 2024-11-05 | $76.86M 10-Q · filed 2024-11-05 | $99.67M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | $27.66M 10-Q · filed 2024-08-06 | $52.01M 10-Q · filed 2024-08-06 | $74.82M derived: sum of 3 quarters · filed 2025-05-14 | $92.89M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | $24.34M 10-Q · filed 2025-05-14 | $47.15M derived: sum of 2 quarters · filed 2025-05-14 | $65.23M derived: sum of 3 quarters · filed 2025-05-14 | $81.62M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $40.88M derived: sum of 2 quarters · filed 2025-03-10 | $57.28M derived: sum of 3 quarters · filed 2025-03-10 | $75.64M 10-K · filed 2025-03-10 |
| 2023-09-30 | $18.07M 10-Q · filed 2024-11-05 | $34.47M derived: sum of 2 quarters · filed 2024-11-05 | $52.84M 10-Q · filed 2024-11-05 | $72.37M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $16.39M 10-Q · filed 2024-08-06 | $34.76M 10-Q · filed 2024-08-06 | $54.30M derived: sum of 3 quarters · filed 2024-08-06 | $71.21M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $18.37M 10-Q · filed 2024-05-07 | $37.90M derived: sum of 2 quarters · filed 2024-05-07 | $54.81M derived: sum of 3 quarters · filed 2024-05-07 | $70.20M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $19.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $36.45M derived: sum of 2 quarters · filed 2024-03-12 | $51.84M derived: sum of 3 quarters · filed 2024-03-12 | $68.67M 10-K · filed 2024-03-12 |
| 2022-09-30 | $16.91M 10-Q · filed 2023-11-07 | $32.30M derived: sum of 2 quarters · filed 2023-11-07 | $49.14M 10-Q · filed 2023-11-07 | $67.90M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $15.39M 10-Q · filed 2023-08-08 | $32.23M 10-Q · filed 2023-08-08 | $50.99M derived: sum of 3 quarters · filed 2023-08-08 | $65.25M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $16.84M 10-Q · filed 2023-05-09 | $35.60M derived: sum of 2 quarters · filed 2023-05-09 | $49.86M derived: sum of 3 quarters · filed 2023-05-09 | $62.51M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $18.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $33.02M derived: sum of 2 quarters · filed 2023-03-22 | $45.67M derived: sum of 3 quarters · filed 2023-03-22 | $56.65M 10-K · filed 2023-03-22 |
| 2021-09-30 | $14.26M 10-Q · filed 2022-11-10 | $26.92M derived: sum of 2 quarters · filed 2022-11-10 | $37.89M 10-Q · filed 2022-11-10 | $49.16M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $12.65M 10-Q · filed 2022-08-15 | $23.63M 10-Q · filed 2022-08-15 | $34.90M derived: sum of 3 quarters · filed 2022-08-15 | $63.21M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $10.97M 10-Q · filed 2022-05-10 | $22.24M derived: sum of 2 quarters · filed 2022-05-10 | $50.56M derived: sum of 3 quarters · filed 2022-05-10 | $60.11M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $39.59M derived: sum of 2 quarters · filed 2022-03-15 | $49.13M derived: sum of 3 quarters · filed 2022-03-15 | $57.04M 10-K · filed 2022-03-15 |
| 2020-09-30 | $28.32M 10-Q · filed 2021-11-09 | $37.86M derived: sum of 2 quarters · filed 2021-11-09 | $45.77M 10-Q · filed 2021-11-09 | $52.54M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $9.55M 10-Q · filed 2021-08-11 | $17.45M 10-Q · filed 2021-08-11 | $24.22M derived: sum of 3 quarters · filed 2021-08-11 | $28.54M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $7.91M 10-Q · filed 2021-05-12 | $14.67M derived: sum of 2 quarters · filed 2021-05-12 | $18.99M derived: sum of 3 quarters · filed 2021-05-12 | $23.55M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $11.09M derived: sum of 2 quarters · filed 2021-03-25 | $15.64M derived: sum of 3 quarters · filed 2021-03-25 | $20.81M 10-K · filed 2021-03-25 |
| 2019-09-30 | $4.32M 10-Q · filed 2020-11-12 | $8.87M derived: sum of 2 quarters · filed 2020-11-12 | $14.04M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $4.55M 10-Q · filed 2020-09-03 | $9.72M 10-Q · filed 2020-09-03 |